Search Bar & Filters
Found 19 Actively Recruiting clinical trials
Actively Recruiting
This research aims to observe and track growth patterns and the clinical progression of Hypochondroplasia HCH in children. It focuses on collecting various growth measurements and other relevant data over time to better understand this condition. The study is sponsored by BioMarin Pharmaceutical and involves children diagnosed with Hypochondroplasia, up to 15 years old. Participants include children confirmed to have Hypochondroplasia through genetic testing. The study is observational, meaning there are no experimental treatments involved. Children will be monitored regularly to record changes in growth and body proportions, with data collection occurring every six months over the course of the study, which may last up to 15 years. Throughout the study, children will undergo assessments every six months to measure growth velocity, height, body mass index BMI, and body segment ratios. Quality of life and severity impressions from both patients and caregivers will be evaluated annually. Researchers will also track medical events, use of growth hormone treatments, and any limb lengthening surgeries. This long-term follow-up allows for comprehensive monitoring of growth and health outcomes in children with Hypochondroplasia.
Actively Recruiting
Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.
Actively Recruiting
Researchers are evaluating whether combining ASP-1929 photoimmunotherapy PIT with pembrolizumab improves treatment outcomes for patients with locoregional recurrent squamous cell carcinoma of the head and neck HNSCC without distant metastases. This phase 3 randomized study aims to compare the effectiveness and safety of ASP-1929 PIT plus pembrolizumab against pembrolizumab alone or pembrolizumab combined with chemotherapy as first-line treatments. The main goal is to see if the combination improves overall survival for eligible patients. Participants will be randomly assigned in a 221 ratio to one of three treatment groups ASP-1929 PIT at a dose of 320 mgm plus pembrolizumab, ASP-1929 PIT at 640 mgm plus pembrolizumab, or a control group receiving standard care with either pembrolizumab alone or pembrolizumab plus chemotherapy according to the physicians choice. ASP-1929 PIT involves an intravenous infusion followed by illumination of the tumor with red light using a special laser system. Pembrolizumab is given as an intravenous infusion every 3 or 6 weeks. Chemotherapy options include carboplatin, cisplatin, 5-fluorouracil, paclitaxel, or docetaxel for up to 6 cycles. Treatment with ASP-1929 PIT and pembrolizumab may continue for up to 24 months. During the study, participants will undergo regular assessments including imaging evaluations to measure tumor response, safety monitoring for adverse events, and quality of life questionnaires. Researchers will track overall survival and other outcomes such as response rates and progression-free survival for up to about 48 months. Pharmacokinetic and immunogenicity tests will also be conducted in the experimental arms. Participants will have ongoing evaluations throughout the treatment period and follow-up to monitor effectiveness and safety.
Actively Recruiting
Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.
Actively Recruiting
Researchers are studying repotrectinib TPX-0005 in adults and adolescents with advanced solid tumors that have specific gene rearrangements in ALK, ROS1, or NTRK1-3. The trial aims to find the safest and most effective dose in Phase 1, and then evaluate how well the drug works in Phase 2 across different patient groups with these gene changes. This includes patients with tumors that have spread and those with brain involvement, focusing on response rates and survival outcomes. The study involves oral doses of repotrectinib. Phase 1 includes dose escalation to determine dose-limiting toxicities, maximum tolerated dose, and recommended dose for Phase 2. A sub-study also examines drug interactions with midazolam. In Phase 2, participants are assigned to one of six groups based on their tumor type and prior treatments, including different lines of targeted therapy and chemotherapy. Treatments continue according to protocol with regular monitoring. Participants will have measurable tumors confirmed by imaging reviewed centrally. They undergo physical exams, lab tests, and safety assessments throughout the study. Researchers measure response rates, duration of response, progression-free survival, overall survival, and clinical benefit over several years. The study monitors drug levels in blood and evaluates safety closely. Participation may last years with follow-up to assess long-term outcomes and effects on brain metastases.
Actively Recruiting
Researchers are evaluating how efgartigimod affects thyroid function in adults with Graves Disease GD, focusing on its safety, tolerability, and impact on antibody levels and immune response. This Phase 3 study compares efgartigimod with placebo in adults whose GD is not adequately controlled with antithyroid drugs, aiming to better understand its effects on thyroid hormone levels and disease control. Participants will be randomly assigned to receive either efgartigimod PH20 subcutaneous injections via prefilled syringe or placebo during the initial double-blinded treatment period part A and treatmentobservation period part B. Those who respond may continue to an open-label treatmentobservation phase part C receiving efgartigimod. Treatment and observation durations vary, with total participation lasting from approximately 63 to 135 weeks depending on individual response. During the study, participants will undergo regular assessments of thyroid hormone levels fT3, fT4, TSH, antibody levels, and immune responses to evaluate treatment effects. Safety and tolerability will be closely monitored, and researchers will track changes in thyroid-related symptoms and quality of life. The main outcome is the percentage of participants achieving normal thyroid hormone levels without antithyroid drugs by week 24. Participants will be followed for up to nearly three years to observe long-term effects and safety.
Actively Recruiting
Researchers are evaluating the efficacy and safety of NIO752 in people with Progressive Supranuclear Palsy PSP in this Phase III randomized, placebo-controlled study. The trial aims to understand how well NIO752 works in treating PSP Richardson syndrome, a condition characterized by certain neurological symptoms with onset less than 5 years ago. Participants with mild to moderate PSP and specific functional abilities are included to assess the treatments impact. Participants will be randomly assigned in a 21 ratio to receive either NIO752, an antisense oligonucleotide solution, or a placebo solution. This double-blind treatment phase is followed by an open-label extension where all participants can continue receiving NIO752. The study measures changes in disease severity and function over 72 weeks using several scales and cognitive tests. During the study, participants and their reliable study partners will attend visits for assessments including neurological exams, cognitive tests, and brain MRI scans. Researchers will monitor changes in PSP rating scales, daily living activities, cognitive function, and relevant biomarkers in cerebrospinal fluid. Safety is closely tracked through adverse event reporting. The total study duration includes 72 weeks of treatment followed by long-term monitoring until study completion.
Actively Recruiting
Researchers are evaluating treatments for people with advanced non-small cell lung cancer NSCLC that has spread or cannot be controlled by current therapies. This study focuses on patients whose cancer cells have specific changes called HER2 mutations, which cause abnormal cell growth. The main goal is to compare the effectiveness and safety of a new drug called sevabertinib against the standard treatment for this condition. Participants will be randomly assigned to one of two groups one group will take sevabertinib tablets twice daily, and the other will receive the current standard treatment, which includes pembrolizumab combined with platinum-based chemotherapy given by vein infusion every 21 days. Those on standard treatment may switch to sevabertinib if their cancer worsens. Treatment continues as long as participants benefit and do not have severe side effects. During the study, participants will undergo scans like CT, PET, MRI, or X-rays to monitor their cancer. Health assessments include blood and urine tests, heart checks using electrocardiograms and echocardiograms, pregnancy tests when needed, and evaluations of how participants feel and any medical problems they experience. The main outcome measured is how long participants live without their cancer progressing, with other outcomes including overall survival and response rates. The study lasts up to about 4 years, with ongoing monitoring for safety and patient well-being.
Actively Recruiting
This research aims to evaluate the long-term safety and tolerability of brivaracetam in children and adolescents with epilepsy, including those who participated in earlier studies or are newly enrolled in Japan with partial-onset seizures. The study also seeks to assess pharmacokinetic data in Japanese participants. The study is an open-label, single-arm, multicenter trial focusing on pediatric epilepsy treatment with brivaracetam. Participants will receive brivaracetam tablets or oral solution administered twice daily in two equal doses. Dosage varies based on weight up to 5 mgkgday for those weighing 11 to less than 20 kg, up to 4 mgkgday for those weighing 20 to less than 50 kg, and no more than 200 mgday. Directly enrolled participants in Japan will receive 1 to 4 mgkgday, not exceeding 200 mgday. The study includes long-term follow-up for up to 5 years. During the study, participants will be monitored for treatment-emergent adverse events, serious adverse events, and adverse events leading to discontinuation of the drug. Evaluations occur from Day 1 through safety visits over the 5-year period. Researchers will assess safety, tolerability, and pharmacokinetics. The total participation duration extends up to 5 years, with ongoing safety evaluations throughout this time.
Actively Recruiting
Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.
1-10 of 19
1